longitudin
studi
cytokin
product
neonat
acquir
infect
none
asian
chines
children
determin
whether
monitor
cytokin
product
could
contribut
better
manag
pediatr
patient
infect
patient
ten
asian
eurasian
children
infect
mothertochild
transmiss
follow
year
treatment
highli
activ
antiretrovir
therapi
haart
number
unstimul
mitogenactiv
cytokinesecret
cell
ifngamma
interleukin
il
tnfalpha
measur
elispot
assay
frequent
interv
correl
sought
cell
count
viral
load
mitogenstimul
cell
directli
associ
recoveri
cell
correl
viral
load
found
con
ainduc
ifngamma
con
ainduc
unstimul
suggest
cytokin
either
suppress
high
viru
level
higher
cytokin
level
suppress
viru
ifngamma
cell
induc
pha
con
andor
sac
tend
increas
first
year
treatment
declin
thereaft
alter
cytokin
profil
associ
advers
clinic
event
littl
evid
indic
monitor
cytokin
enzymelink
immunospot
elispot
could
contribut
pediatr
patient
manag
advent
highli
activ
antiretrovir
therapi
haart
human
immunodefici
viru
type
control
prolong
period
although
viru
elimin
treatment
failur
occur
due
develop
drugresist
mutat
chronic
immun
hyperactiv
rais
tcell
turnov
due
continu
viral
replic
antigen
stimul
present
even
haart
decreas
viral
load
undetect
level
proinflammatori
regulatori
cytokin
produc
chronic
immun
stimul
proinflammatori
cytokin
interleukin
il
tumor
necrosi
factoralpha
tnfalpha
contribut
tissu
patholog
especi
brain
induc
transcript
latent
type
regulatori
cytokin
suppress
type
cytokin
induc
polyclon
bcell
activ
lymphomagenesi
autoantibodi
product
manifest
allergi
type
cytokin
interferon
ifn
gamma
import
antivir
cellmedi
immun
long
cours
infect
type
cytokin
gradual
come
predomin
type
cytokin
although
find
univers
accept
studi
vitro
cytokin
product
neonat
acquir
infect
asian
chines
children
enzymelink
immunospot
elispot
system
measur
unstimul
mitogenactiv
cytokin
secret
cell
evalu
context
wish
know
whether
monitor
cytokin
product
addit
cell
count
viral
load
could
provid
addit
use
inform
pediatr
patient
infect
treat
haart
hope
identifi
cytokin
profil
characterist
either
clinic
improv
diseas
progress
manipul
toward
desir
profil
might
attempt
studi
approv
institut
review
board
hong
kong
west
hospit
cluster
univers
hong
kong
inform
consent
obtain
parent
subject
clinic
find
patient
describ
previous
ten
asian
eurasian
children
girl
boy
infect
mothertochildtransmiss
initi
diagnos
age
median
month
follow
median
month
tabl
time
diagnosi
children
low
cell
count
compar
agespecif
normal
rang
median
plasma
rna
level
copiesml
children
lymphadenopathi
andor
hepatosplenomegali
diagnosi
one
girl
patient
develop
nktcell
lymphoma
caus
death
fatal
studi
period
patient
infecti
complic
includ
pneumocysti
carinii
pneumonia
viral
pneumonia
dissemin
penicillium
marneffei
thrush
tinea
capiti
herp
simplex
complic
includ
neutropenia
patient
hepat
anemia
asthma
andor
rhiniti
patient
start
haart
immedi
confirm
infect
treat
nucleosid
revers
transcriptas
inhibitor
zidovudin
lamivudin
didanosin
stavudin
andor
abacavir
plu
proteas
inhibitor
indinavir
nelfinavir
kaletra
lopinavir
ritonavir
ritonavir
amprenavir
nonnucleosid
revers
transcriptas
inhibitor
nevirapin
detail
given
tabl
patient
examin
blood
hematolog
virolog
immunolog
evalu
taken
everi
month
first
cytokin
evalu
perform
within
month
start
haart
patient
within
month
patient
month
patient
number
cytokinesecret
cell
unstimul
cultur
cultur
stimul
tcell
activ
phytohemagglutinin
pha
concanavalin
con
monocyt
activ
staphylococcu
aureu
cowan
sac
determin
use
elispot
assay
detail
adapt
method
specif
reproduc
intraand
interassay
cv
respect
report
result
normal
control
evalu
studi
period
remain
stabl
within
establish
refer
rang
briefli
peripher
blood
mononuclear
cell
pbmc
separ
lymphoprep
nycom
oslo
norway
within
hour
blood
collect
ad
multiscreen
plate
millipor
bedford
massachusett
usa
previous
coat
overnight
cytokin
captur
antibodi
pharmingen
san
diego
california
usa
tnfalpha
ifngamma
mcgml
nahco
ph
block
fetal
calf
serum
fc
cultur
medium
rpmi
least
hour
duplic
cultur
tnfalpha
ifngamma
viabl
cellswel
rpmi
fc
without
pha
final
concentr
mcgml
con
mcgml
sac
vv
incub
hour
co
cell
wash
phosphatebuff
salin
contain
tween
pbst
plate
incub
sequenti
biotinyl
detect
anticytokin
antibodi
pharmingen
mcgml
pbst
minut
streptavidinalkalin
phosphatas
sigma
st
loui
missouri
usa
vv
pbst
minut
tetrazolium
calbiochem
la
jolla
california
usa
minut
room
temperatur
plate
wash
extens
pbst
incub
salin
remov
phosphat
prior
addit
phosphatas
substrat
color
develop
stop
pathogen
inactiv
immers
clorox
bleach
follow
rins
tap
allow
plate
dri
hour
blue
spot
correspond
cytokinesecret
cell
count
microscopi
result
express
pbmc
thelper
cell
tcytotox
cell
enumer
use
commerci
monoclon
antibodi
beckman
coulter
miami
florida
usa
dual
color
flow
cytometri
epic
xlmcl
coulter
white
cell
differenti
count
perform
standard
method
rna
quantit
amplicor
monitor
roch
diagnost
corpor
branchburg
new
jersey
usa
standard
method
perform
accord
manufactur
recommend
measur
rang
rna
copiesml
correl
number
cytokinesecret
cell
proport
absolut
number
cell
ratio
viru
load
evalu
multipl
regress
analysi
without
logarithm
transform
linear
regress
line
plot
parametr
rather
nonparametr
statist
use
despit
small
number
patient
wish
deriv
formula
estim
cytokin
level
predict
viral
load
lymphocyt
subset
count
log
transform
perform
viral
load
data
skew
kurtosi
raw
data
respect
becam
respect
log
transform
curv
number
cytokinesecret
cell
plot
length
treatment
haart
fit
nonlinear
regress
statist
softwar
use
graphpad
prism
version
window
graphpad
softwar
san
diego
california
usa
wwwgraphpadcom
twelv
asian
eurasian
children
infect
mothertochild
transmiss
treat
haart
time
diagnosi
median
month
old
initi
diagnos
therefor
heterogen
regard
immunolog
matur
durat
infect
extent
immunodefici
due
high
viral
load
low
cell
count
diagnos
enter
studi
one
child
die
lymphoma
age
month
receiv
haart
month
time
cell
increas
viral
load
decreas
undetect
end
studi
surviv
patient
well
thrive
seven
normal
higherthannorm
circul
cellsmcl
patient
still
reduc
number
andor
percentag
plasma
rna
consist
level
detect
surviv
children
studi
close
undetect
plasma
multipl
regress
correl
number
pbmc
tcell
count
pediatr
patient
treat
haart
rna
achiev
month
median
month
cytokin
cultur
condit
studi
patient
receiv
haart
correspond
valu
cell
correspond
valu
plasma
rna
copiesml
avail
data
use
examin
whether
cytokin
product
correl
diseas
progress
ifngamma
elispot
undetect
unstimul
pbmc
report
previous
number
phaor
con
astimul
cell
increas
recoveri
defici
correl
directli
absolut
count
percentag
ratio
invers
percentag
multipl
regress
analysi
data
could
describ
ifngamma
con
ainduc
unstimul
cell
increas
significantli
viru
load
fell
figur
data
describ
follow
equat
log
viral
load
log
con
log
con
log
unstimul
data
elispot
assay
plot
durat
haart
number
ifngamma
cell
tend
increas
first
year
treatment
declin
thereaft
chang
tnfalphasecret
cell
time
less
appar
see
figur
figur
effect
matur
immun
system
gener
cytokin
product
particular
well
understood
especi
context
treatment
haart
wish
know
whether
regular
monitor
mitogeninduc
cytokin
product
addit
cell
count
viru
load
would
valid
measur
immunolog
compet
therefor
use
addit
paramet
clinic
monitor
also
look
correl
cytokin
product
viral
load
cell
number
hope
identifi
cytokin
profil
associ
favor
outcom
howev
limit
hivinfect
children
avail
studi
hong
kong
statist
bia
could
occur
due
heterogen
regard
immunolog
matur
time
diagnosi
durat
infect
extent
immunodefici
start
haart
cytokin
studi
correl
posit
increas
tcell
percentag
absolut
number
increas
ratio
treatment
exogen
shown
increas
peripher
expans
cell
product
also
correl
tcell
increas
surprisingli
popul
includ
major
cytotox
effector
cell
hiv
correl
viral
load
rna
copiesml
correl
invers
con
ainduc
ifngamma
con
ainduc
unstimul
suggest
cytokin
might
involv
control
level
imposs
distinguish
possibl
high
level
viru
suppress
product
cytokin
andor
viru
surviv
better
product
cytokin
limit
contrast
find
previou
studi
report
plasma
declin
adequ
virolog
immunolog
respons
haarttreat
adult
differ
race
age
patient
studi
may
contribut
conflict
find
also
contrast
studi
ifngamma
tnfalpha
declin
adequ
virolog
immunolog
respons
haarttreat
adult
howev
reuben
colleagu
found
increas
plasma
ifngamma
viru
suppress
pediatr
patient
resino
cowork
found
lower
phainduc
tnfalpha
ifngamma
pbmc
p
b
con
ainduc
cell
pbmc
p
c
unstimul
pbmc
p
rapidprogressor
children
longterm
asymptomat
therefor
possibl
cytokin
may
interact
differ
hiv
children
adult
also
born
mind
enumer
cytokinesecret
cell
follow
vitro
mitogen
stimul
isol
pbmc
unlik
compar
directli
cytokin
quantit
plasma
novel
find
con
ainduc
neg
correl
viral
load
line
abil
inhibit
phorbol
esterstimul
express
chronic
infect
promonocyt
cell
effect
hiv
cultur
merit
studi
observ
chang
time
suggest
type
cytokin
product
tend
predomin
type
cytokin
describ
report
instead
observ
presum
desir
increas
number
type
ifngamma
type
pbmc
first
year
treatment
haart
maintain
beyond
time
figur
known
whether
reduc
trend
natur
presag
fail
immun
protect
hope
lessen
immun
hyperactiv
continu
observ
small
cohort
patient
allow
us
determin
whether
chang
cytokin
product
relat
eventu
clinic
outcom
elispot
assay
use
investig
optim
reproduc
sensit
requir
special
equip
rel
easi
perform
inexpens
approxim
us
per
patient
cytokin
differ
activ
condit
previous
use
system
investig
vitro
cytokin
product
number
clinic
situat
assay
perform
favor
data
group
patient
pool
statist
comparison
wide
variat
valu
differ
subject
daytoday
variabl
due
factor
subclin
ill
mild
tissu
injuri
possibl
variabl
stress
level
ethic
feasibl
either
healthi
match
pediatr
control
group
untreat
pediatr
hiv
control
group
present
studi
limit
comparison
cytokin
profil
individu
patient
time
rel
good
poor
health
improv
worsen
cell
count
viral
load
unabl
identifi
cytokin
profil
associ
predict
hivrel
clinic
event
cytokin
profil
use
mitogenstimul
elispot
assay
therefor
unlik
import
clinic
measur
could
influenc
improv
accuraci
patient
manag
decis
brian
jone
phd
disclos
relev
financi
relationship
susan
ss
chiu
md
disclos
relev
financi
relationship
wilfr
hs
wong
mmedsci
disclos
relev
financi
relationship
wilina
wl
lim
md
disclos
relev
financi
relationship
yulung
lau
md
disclos
relev
financi
relationship
number
tnfalphasecret
cell
pediatr
patient
treat
haart
figur
number
tnfalphasecret
cell
pediatr
patient
treat
haart
cytokinesecret
cell
tend
remain
stabl
studi
period
curv
fit
nonlinear
regress
